Close
Close
Treatment News

Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting

3.0
3.0 from 5 votes
Thursday, April 18, 2019

Learn more about:

Access Programs

BERKELEY, Calif. - Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical stage biopharmaceutical company developing therapies in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways, announced that abstracts pertaining to the company's lead programs, STING agonist ADU-S100 and anti-APRIL antibody BION-1301, will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 to June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.

Details of the oral presentation are as follows:

ADU-S100 (MIW815)
Abstract 2507: Phase Ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced/metastatic solid tumors or lymphomas.
Presenter: Dr. Funda Meric-Bernstam, MD Anderson Cancer Center
Session: Oral Abstract Session: Developmental Immunotherapy and Tumor Immunobiology
Date/Time/Location: Sunday, June 2, 2019, 8:00 AM – 11:00 AM CDT in Hall D2

Details of the poster presentations are as follows:

BION-1301
Abstract 8012 / Poster Board #338: Safety and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
Presenter: Dr. William Bensinger, Fred Hutchinson Cancer Research Center
Session: Poster Discussion Session: Hematologic Malignancies – Plasma Cell Dyscrasia
Date/Time/Location:  Poster Display: Monday, June 3, 2019, 8:00 AM – 11:00 AM CDT in Hall A
                                     Poster Discussion: Monday, June 3, 2019, 1:15 PM – 2:45 PM CDT in E450

Abstract 8022 / Poster Board #348: Pharmacokinetics, pharmacodynamics, safety, and tolerability of BION-1301 in adults with relapsed or refractory multiple myeloma.
Session: Poster Session: Hematologic Malignancies – Plasma Cell Dyscrasia
Date/Time/Location: Poster Display: Monday June 3, 2019, 8:00 AM – 11:00 AM CDT in Hall A

About Aduro
Aduro Biotech, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Aduro's product candidates in the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways are being investigated in cancer, autoimmune and inflammatory diseases. ADU-S100 (MIW815), which potentially activates the intracellular STING receptor for a potent tumor-specific immune response, is being evaluated in patients with cutaneously accessible metastatic solid tumors or lymphomas. BION-1301, a fully blocking monoclonal antibody that blocks APRIL binding to both the BCMA and TACI receptors, is being evaluated in multiple myeloma and as a potential treatment for IgA nephropathy. Aduro is collaborating with a number of leading global pharmaceutical companies to help expand and drive its product pipeline. For more information, please visit www.aduro.com.

 

Contacts:
Investor Relations
Noopur Liffick
510-809-2465
investors@aduro.com

Media
Aljanae Reynolds
510-809-2452
press@aduro.com

Source: Aduro BioTech
3.0
3.0 from 5 votes
Free Newsletter
Related Videos